Abstract: The invention relates to oligofluorinated coatings and their use in drag delivery The oligofluorinated coatings are compositions comprising formula (XVII). These coatings are used in a method of delivering a biologically active agent to a tissue surface in a mammalian tissue This method occurs by contacting the surface with the coating including an oligofluorinated oligomer and a biologically active agent wherein the coating resides on the tissue surface and release the biologically active agent to the tissue surface.

Abstract: The invention features grafted polymer systems for use in medical devices and/or for the delivery of active agents. The grafted polymers include at least one transport moiety, a linear backbone segment, and a pendant segment.

Abstract: A pharmaceutically-active polymeric compound of the general formula (I), Y-[Yn-LINK B-X]m-LINK B??(I) wherein (i) X is a coupled biological coupling agent of the general formula (II) Bio-LINK A-Bio??(II) wherein Bio is a biologically active agent fragment or precursor thereof linked to LINK A through a hydrolysable covalent bond; and LINK A is a coupled central flexible linear first segment of <2000 theoretical molecular weight linked to each of said Bio fragments; (ii) Y is LINK B-OLIGO; wherein (a) LINK B is a coupled second segment linking one OLIGO to another OLIGO and an OLIGO to X or precursor thereof; and (b) OLIGO is a short length of polymer segment having a molecular weight of less than 5,000 and comprising less than 100 monomeric repeating units; (iii) m is 1-40; and (iv) n is selected from 2-50. The compounds are useful as biomaterials, particularly, providing antibacterial activity in vivo.

Abstract: The invention relates to surface modifying macromolecules (SMMs) having high degradation temperatures and their use in the manufacture of articles made from base polymers which require high temperature processing. The surface modifier is admixed with the base polymer to impart alcohol and water repellency properties.

Abstract: The invention relates to surface modifying macromolecules (SMMs) having high degradation temperatures and their use in the manufacture of articles made from base polymers which require high temperature processing. The surface modifier is admixed with the base polymer to impart alcohol and water repellency properties.

Abstract: The invention relates to surface modifying macromolecules (SMMs) having high degradation temperatures and their use in the manufacture of articles made from base polymers which require high temperature processing. The surface modifier is admixed with the base polymer to impart alcohol and water repellency properties.

Abstract: The invention relates to surface modifying macromolecules (SMMs) having high degradation temperatures and their use in the manufacture of articles made from base polymers which require high temperature processing. The surface modifier is admixed with the base polymer to impart alcohol and water repellency properties.

Abstract: The invention relates to surface modifying macromolecules (SMMs) having high degradation temperatures and their use in the manufacture of articles made from base polymers which require high temperature processing. The surface modifier is admixed with the base polymer to impart alcohol and water repellency properties.

Abstract: A pharmaceutically-active polymeric compound of the general formula (I), Y-[Yn-LINK B-X]m-LINK B??(I) wherein (i) X is a coupled biological coupling agent of the general formula (II) Bio-LINK A-Bio??(II) wherein Bio is a biologically active agent fragment or precursor thereof linked to LINK A through a hydrolysable covalent bond; and LINK A is a coupled central flexible linear first segment of <2000 theoretical molecular weight linked to each of said Bio fragments; (ii) Y is LINK B-OLIGO; wherein (a) LINK B is a coupled second segment linking one OLIGO to another OLIGO and an OLIGO to X or precursor thereof; and (b) OLIGO is a short length of polymer segment having a molecular weight of less than 5,000 and comprising less than 100 monomeric repeating units; (iii) m is 1-40; and (iv) n is selected from 2-50. The compounds are useful as biomaterials, particularly, providing antibacterial activity in vivo.

Abstract: The invention features the use of a matrix consisting of low molecular weight components for use as a self-eliminating coating for implantable medical devices. The matrix coatings can be used to enhance biocompatibility and to control the local delivery of biologically active agents.

Abstract: The invention features oligofluorinated cross-linked polymers and their use in the manufacture of articles and coating surfaces.

Abstract: The present invention relates to a fibrous scaffold for use as a substrate in soft tissue applications, in particular for preparing annulus fibrosus (AF) tissue. In aspects, the present invention also relates to an engineered biological material comprising AF tissue; constructs comprising one or more engineered biological materials; methods for producing the biological materials and constructs; and methods of using the biological materials and constructs.

Abstract: A sintering schedule to allow the reliable formation of inorganic or ceramic materials, exemplified using porous calcium polyphosphate samples to be used for forming novel implants for bone interfacing applications. The key to the successful definition of the process was the determination of the factors affecting the crystallization temperature of the powders that are gravity sintered to form porous samples of desired density and with a pore size range suitable for the particular application.

Abstract: The invention relates to surface modifying macromolecules (SMMs) having high degradation temperatures and their use in the manufacture of articles made from base polymers which require high temperature processing. The surface modifier is admixed with the base polymer to impart alcohol and water repellency properties.

Abstract: The invention features polymers noncovalently complexed with a biologically active agent. The polymer complexes include at least one shielding moiety covalently tethered to at least one complexing moiety, which is complexed with at least one biologically active agent.

Abstract: A pharmaceutically-active polymeric compound of the general formula (I), Y-[Yn-LINK B-X]m-LINK B??(I) wherein (i) X is a coupled biological coupling agent of the general formula (II) Bio-LINK A-Bio??(II) wherein Bio is a biologically active agent fragment or precursor thereof linked to LINK A through a hydrolysable covalent bond; and LINK A is a coupled central flexible linear first segment of <2000 theoretical molecular weight linked to each of said Bio fragments; (ii) Y is LINK B-OLIGO; wherein (a) LINK B is a coupled second segment linking one OLIGO to another OLIGO and an OLIGO to X or precursor thereof; and (b) OLIGO is a short length of polymer segment having a molecular weight of less than 5,000 and comprising less than 100 monomeric repeating units; (iii) m is 1-40; and (iv) n is selected from 2-50. The compounds are useful as biomaterials, particularly, providing antibacterial activity in vivo.

Abstract: A pharmaceutically-active polymeric compound of the general formula (I), Y?[Yn?LINK B?X]m?LINK B??(I) wherein (i) X is a coupled biological coupling agent of the general formula (II) Bio?LINK A?Bio??(II) wherein Bio is a biologically active agent fragment or precursor thereof linked to LINK A through a hydrolysable covalent bond; and LINK A is a coupled central flexible linear first segment of <2000 theoretical molecular weight linked to each of said Bio fragments; (ii) Y is LINK B-OLIGO; wherein (a) LINK B is a coupled second segment linking one OLIGO to another OLIGO and an OLIGO to X or precursor thereof; and (b) OLIGO is a short length of polymer segment having a molecular weight of less than 5,000 and comprising less than 100 monomeric repeating units; (iii) m is 1-40; and (iv) n is selected from 2-50. The compounds are useful as biomaterials, particularly, providing antibacterial a.i. in vivo.

Abstract: A sintering schedule to allow the reliable formation of inorganic or ceramic materials, exemplified using porous calcium polyphosphate samples to be used for forming novel implants for bone interfacing applications. The key to the successful definition of the process was the determination of the factors affecting the crystallization temperature of the powders that are gravity sintered to form porous samples of desired density and with a pore size range suitable for the particular application.

Abstract: The present invention relates to membranes useful in the separation of water from a solution containing volatile organic compounds and water. The membranes may be used in dehydrating an organic/water mixture to purify an organic when an organic is of interest or, alternatively, producing pure water from an organic/water mixture when clean water is of interest. The membranes include a hydrophilic base polymer, an optional pore-forming polymer and a surface modifying macromolecule (SMM) which imparts surface hydrophobicity to the membrane.